Microsoft aiming early disease screening tool a reality


The latest collaboration between Adaptive Biotechnologies, and Microsoft aims to map the genetic code of the human immune system. The efforts will go in detecting cancers and other diseases in their earliest stage.

Chad Robins, Adaptive CEO and Peter Lee, Corporate VP, Microsoft AI and Research shared greater details of the partnership at the recently held 36th Annual J.P. Morgan Healthcare Conference. The partnership will eventually lead to a better understanding of overall human health.

By combining Adaptive’s powerful immune sequencing technologies with Microsoft’s research and large-scale machine learning and cloud computing capabilities, the joint efforts will create individual disease diagnostics and ultimately a universal diagnostic – all from a simple blood test. Microsoft has made a financial investment into Adaptive, in addition to bringing research and large-scale machine learning and cloud computing capabilities.

The immune system is nature’s way to routinely scan and read any signal of disease– in the body, and holds the genetic code that can give insights into detecting these diseases. Both have come together to translate this genetic code into simple blood-based diagnostics that are broadly accessible to people around the world.